瑞舒伐他汀和阿托伐他汀对高胆固醇血症患者血浆脂蛋白相关性磷脂酶A2的影响

目的 比较瑞舒伐他汀和阿托伐他汀对高胆固醇血症惠者血浆脂蛋白相关性磷脂酶A2(LpPLA2)活性的影响.方法 本试验为随机、双盲研究.在4周治疗性生活方式改善后,符合入选标准的高胆固醇血症患者随机分入瑞舒伐他汀5 mg组(瑞舒伐他汀5 mg/d)、瑞舒伐他汀10 mg组(瑞舒伐他汀10 mg/d)和阿托伐他汀10 mg组(阿托伐他汀10 mg/d),治疗8周.药物治疗前和治疗8周后测定血清总胆固醇、血清甘油三酯、血清低密度脂蛋白胆固醇、血清高密度脂蛋白胆固醇水平以及血浆Lp-PLA2活性.结果 60例高胆固醇血症患者入选.治疗前各组血脂参数和血浆Lp-PLA2活性相似.治疗8周后,瑞舒伐他汀5 mg组、瑞舒伐他汀10 mg组和阿托伐他汀10 mg组血清低密度脂蛋白胆固醇(LDL-C)水平分别降低35%、41%和36%,血浆Lp-PLA2活性降低幅度分别为15%、17%和15%.血浆Lp-PLA2活性和血清LDL-C水平相关(r=0.507,P=0.00).结论 高胆固醇血症患者瑞舒伐他汀和阿托伐他汀治疗8周后,血浆Lp-PLA2活性均显著下降.血浆Lp-PLA2活性和血清LDL-C水平相关.

The effect of rosuvastatin and atrovastatin on plasma lipoprotein-associated phospholipase A2 activity in patients with hypercholesterolemia

Objective To evaluate the effect of rosuvastatin and atorvastatin on plasma lipoprotein-associated phospholipase A2(Lp-PLA2)activity in patients with hypercholesterolemia.Methods This was a randomized,double-blind study.After a 4-week therapeutic lifestyle changes period,patients with hypercholesterolemia randomly received rosuvastatin(5mg/d),rosuvastatin (10 mg/d)and atorvastatin(10 mg/d)for 8 weeks.The levels of serum total cholesterol,triglyceride,low-density lipoprotein cholasterol(LDL-C),hish-density lipopretein cholesterol and plasma Lp-PLA2 activity were measured at basetine and active treatment 8 weeks later.Results Sixty patients with hypereholesterolemia were enrolled in the study.Groups were matched in accordance with the baseline characteristics.After statins therapy serum LDL-C decreased by 35%,41%and 36%;plasma Lp-PLA2 activity decreased by 15%,17%and 15%in rosuvastatin(5mg/d),rosuvastatin(10mg/d)and atorvastatin(10mg/d),respectively,The correlations between plasma Lp-PLA2 activity and the level of serum LDL-C(r=0.507,P=0.00)were observod.Condusion The levels of plasma Lp-PLA2 activity are reduced significantly after rosuvastatin and atorvastatin therapy for 8 weeks in patients with hypercholesterolemia.There is correlation between plasma Lp-PLA2 activity and serum LDL-C.